OREANDA-NEWS. February 20, 2012. The Sotex company started the new 2012 year with a significant event, the introduction of a novel injection drug Chondrogarde®. The active substance of Chondrogarde is chondroitin sulfate, a high-molecular-weight mucopolysaccharide essential for the normal function of the hyaline cartilage. It improves calcium and phosphate metabolism in the cartilage tissue, accelerates regenerative processes in the cartilage and stimulates the production of glycosaminoglycans. A therapeutic effect can be observed as early as 2-3 weeks after initiation of treatment: the pain is alleviated, clinical manifestations of reactive synovitis are subsided and the range of movement in the affected joints is increased. Furthermore, Chondrogarde can reduce degenerative changes and accelerate regenerative processes in the cartilage tissue. It is worth noting that the effect is sustained for a long period after the end of the treatment course.

Chondrogarde is supplied in ampoules containing 1 ml No10 as a ready-to-use solution, which sets this medication apart from chondroitin sulfate injection drugs supplied as a lyophilized powder.

Commentary by Vitaliy Smerdov, CEO of FarmFirma Sotex: “The introduction of Chondrogarde is a major step in expanding the product portfolio of the company’s proprietary brands. We are certain that injection drug Chondrogarde will be greatly appreciated in a number of medical fields, primarily in rheumatology, neurology, and traumatology. This is a modern medication, developed in accordance with GMP and the production of this medication will allow us to use ampoule-production lines of our plant with maximum efficiency. Sotex expands the range of high-quality and easily-accessible pharmaceuticals pursuing the national strategy ”Pharma-2020” and increasing the share of Russian-made medications on the pharmaceutical market.”